Clinical Edge Journal Scan

Increased risk for anxiety and depression in children and adolescents with migraine


 

Key clinical point: The odds of anxiety and depression disorders were significantly higher in children and adolescents with migraine compared with control individuals, highlighting the need to routinely screen children and adolescents with migraine for anxiety and depression.

Major finding: Children and adolescents with migraine vs control individuals were at a higher risk for anxiety disorders (odds ratio [OR] 1.93; 95% CI 1.49-2.50), depressive disorders (OR 2.01; 95% CI 1.46-2.78), and mixed internalizing (anxiety and depressive) disorders (OR 4.69; 95% CI 3.08-7.14).

Study details: This was a systematic review of 80 observational studies, of which 51 involving children and adolescents with migraine and control individuals were included in the meta-analysis.

Disclosures: This study was supported by the Alberta Children’s Hospital Research Institute (ACHRI) and Cumming School of Medicine, Canada. SL Orr reported receiving royalties for book publication, grant funding from the Canadian Health Research and ACHRI, and serving on the editorial boards of journals and the American Migraine Foundation.

Source: Falla K et al. Anxiety and depressive symptoms and disorders in children and adolescents with migraine: A systematic review and meta-analysis. JAMA Pediatr. 2022 (Oct 31). Doi: 10.1001/jamapediatrics.2022.3940

Recommended Reading

Real-world efficacy of galcanezumab in high frequency episodic and chronic migraine
Migraine ICYMI
Overlapping initial symptoms demand careful differential diagnosis of migraine and ischemic stroke
Migraine ICYMI
Benefit-risk profiles of lasmiditan, rimegepant, and ubrogepant for acute treatment of migraine
Migraine ICYMI
Association between CGRP-LI levels and migraine treatment outcomes with erenumab
Migraine ICYMI
Changes in gastrointestinal motility with galcanezumab and erenumab in episodic migraine
Migraine ICYMI
Preventive treatment improves cognition and QoL in patients with chronic migraine
Migraine ICYMI
Risk for inpatient constipation similar with erenumab and other anti-CGRP mAb in migraine
Migraine ICYMI
Meta-analysis evaluates safety and efficacy of cinnarizine in migraine
Migraine ICYMI
Commentary: Novel Migraine Treatment Side Effects, November 2022
Migraine ICYMI
New and Improved Devices Add More Therapeutic Options for Treatment of Migraine
Migraine ICYMI